EUVIMEDSkopri EUVIMED
Crossref

Discovery of Novel Inhibitors for WD Repeat‐Containing Protein 5 ( WDR5 )‐ MYC Protein–Protein Interaction

Wei Sun, Huaxing Yu, Jiuyong Ye, Luoheng Qin, Linli Wang, Hailu Yan, Zhimin Zhang, Alex Aliper, Feng Ren, Xiao Ding iD, Alex Zhavoronkov, Dongzhou Liu

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70129 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Wei Sun and 11 co-authors. Institution: Huadong Medicine Company Limited, Hangzhou, China. Major MEDLINE topics: Proto-Oncogene Proteins c-myc, Intracellular Signaling Peptides and Proteins, Drug Discovery. Cited 1 times so far (Crossref); 31 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The WD Repeat‐Containing Protein 5 (WDR5) and MYC interaction is crucial for MYC‐mediated oncogenesis, yet effective therapeutic intervention remains challenging due to the limited efficacy of current treatments targeting WDR5. Herein, we report the discovery of novel WDR5‐MYC protein–protein interaction (PPI) inhibitors with improved potency and drug‐like properties by utilizing a generative chemistry platform along with a physics‐model‐based tool AlChemistry. Initially, three hits were identified with reasonable binding affinity for WDR5, and further refinement through detailed structural analysis led to the discovery of sub‐micromolar affinity compounds (compound 9c‐1 ), which are > 30‐fold better than reported inhibitors. These findings provide a promising starting point for targeting the WDR5‐MYC interaction in MYC‐driven cancers.

Subjects

MeSH terms (MEDLINE)

Proto-Oncogene Proteins c-mycIntracellular Signaling Peptides and ProteinsDrug DiscoveryHumansProtein BindingStructure-Activity RelationshipMolecular Docking SimulationBinding Sites

Author keywords

MYCPPIWDR5generative chemistryphysics‐model‐based tool

Substances

Proto-Oncogene Proteins c-mycWDR5 protein, humanIntracellular Signaling Peptides and Proteins

Authors and institutions

  • Huadong Medicine Company Limited, Hangzhou, China.
  • Insilico Medicine Shanghai Ltd., Shanghai, China.
  • Insilico Medicine AI Limited, Masdar City, UAE.

ORCID profiles: Xiao Ding

Cite

APA

Sun, W., Yu, H., Ye, J., Qin, L., Wang, L., Yan, H., Zhang, Z., Aliper, A., Ren, F., Ding, X., Zhavoronkov, A., & Liu, D. (2025). Discovery of Novel Inhibitors for WD Repeat‐Containing Protein 5 ( WDR5 )‐ MYC Protein–Protein Interaction. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70129

Vancouver

Sun W, Yu H, Ye J, Qin L, Wang L, Yan H, et al. Discovery of Novel Inhibitors for WD Repeat‐Containing Protein 5 ( WDR5 )‐ MYC Protein–Protein Interaction. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70129

BibTeX
@article{Sun2025,
  author = {Sun, Wei and Yu, Huaxing and Ye, Jiuyong and Qin, Luoheng and Wang, Linli and Yan, Hailu and Zhang, Zhimin and Aliper, Alex and Ren, Feng and Ding, Xiao and Zhavoronkov, Alex and Liu, Dongzhou},
  title = {Discovery of Novel Inhibitors for WD Repeat‐Containing Protein 5 ( WDR5 )‐ MYC Protein–Protein Interaction},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70129}
}
Start for free →